Project description
New drug for the treatment of pancreatic cancer
ABTL0812 is a first-in-class oral targeted anticancer compound developed by Ability Pharmaceuticals, that produces autophagy-mediated cytotoxicity in cancer cells. In preclinical studies, ABTL0812 showed efficacy as a single agent and in combination with standard-of-care treatments in in vitro and in animal models of pancreatic cancer, a disease with an unmet clinical need for new therapies. It induced tumor regression without increasing the toxicity associated with chemotherapy and demonstrated safety and well-tolerated toxicities in the first-in-human phase 1/1b clinical trial. In a phase 1/2a clinical trial in endometrial and lung cancer patients, ABTL0812, in combination with the standard-of-care chemotherapy, demonstrated superiority over chemotherapy alone. The EU-funded PanC-ASAP project will start a phase 2 clinical trial in pancreatic cancer to investigate the new drug in combination with the standard-of-care chemotherapy.
Fields of science
Programme(s)
Funding Scheme
SME-2b - SME Instrument (grant only and blended finance)Coordinator
08193 Barcelona
Spain
See on map